{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:42:34Z","timestamp":1789069354678,"version":"build-2803163510"},"reference-count":125,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3158,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01146.x","type":"journal-article","created":{"date-parts":[[2007,1,8]],"date-time":"2007-01-08T18:41:33Z","timestamp":1168281693000},"page":"105-118","source":"Crossref","is-referenced-by-count":36,"title":["Non-nucleoside reverse transcriptase inhibitors: a review"],"prefix":"10.1155","volume":"61","author":[{"given":"L.","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2007,1,8]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1468-1293.2006.00424.x","article-title":"B Gazzard on behalf of the BHIVA Writing Committee British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)","volume":"7","year":"2006","journal-title":"HIV Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for Adult HIV infection: 2006 recommendations of the International Aids Society-USA panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB5|cit5","unstructured":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2006 http:\/\/AIDSinfo.nih.gov"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB6|cit6","first-page":"14","article-title":"HIV Drug Resistance in the United Kingdom: data to end of 2004","volume":"16","author":"Health Protection Agency","year":"2006","journal-title":"CDR Weekly"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01.qai.0000155201.51232.2e","article-title":"French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-na\u00efve chronically infected patients in 2001-2002","volume":"38","author":"Descamps","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/496982","article-title":"Resistance to non-nucleoside reverse-transcriptase inhibitors and prevalence of HIV Type 1 non-B subtypes are increasing among persons with recent infection in Spain","volume":"41","author":"De Mendoza","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB9|cit9","unstructured":"Rinck G Tatt ID Murphy G et\u00a0al. Trends in transmitted antiretroviral drug resistance in men who have sex with men attending genitourinary medicine clinics in England, Wales and Northern Ireland XV International AIDS Conference 2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200501030-00001","article-title":"The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models","volume":"19","author":"Blower","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB12|cit12","unstructured":"Vardavas R Blower S. Antiretrovirals, Africa and the evolution of drug resistant HIV: predictions for Botswana 14th International HIV Drug Resistance Workshop 2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB14|cit14","unstructured":"Molina JM Wilkin A Domingo P et\u00a0al. Once-daily vs. twice -daily lopinavir-ritonavir in antiretroviral-na\u00efve patients: 96-weekresults 3rd IAS Conference on HIV Pathogenesis & Treatment; July 24-27 2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1056\/NEJMoa012354","article-title":"M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB17|cit17","unstructured":"Ananworanich J Nuesch R Le Braz M et\u00a0al. CD4-guided scheduled treatemtn interruptions: low incidence of resistance mutations in the Staccato Trial 13th Conference on Retroviruses and Opportunistic Infections 200\u2003g; Denver"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB18|cit18","volume-title":"GW433908 (908)\/ritonavir (r): 48-week results in PI-experienced patients: A retrospective analysis based on baseline genotype and phenotype","author":"Elston","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB19|cit19","first-page":"30","article-title":"Virological failure and subsequent resistance profiles in subjects exposed to atazanavir","volume":"7","author":"Nathan","year":"2006","journal-title":"HIV Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB20|cit20","volume-title":"Development of de-novo PI-resistance in lopinavir\/ritonavir-monotherapy","author":"Wolf","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB21|cit21","volume-title":"Atazanavir Resistance in a Protease Inhibitor (PI) Na\u00efve Patient Treated with Atazanavir\/Ritonavir Associated with Development of the N88S Mutation in Protease","author":"Coakley","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB22|cit22","unstructured":"Samitala F Kambugu A Katabira E et\u00a0al. Early success of antiretroviral therapy in a sub-Saharan African cohort 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"132","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB25|cit25","volume-title":"95% adherence is not necessary to suppress the majority of individuals to less than 400 copies\/ml on NNRTI regimens","author":"Bangsberg","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB26|cit26","unstructured":"http:\/\/www.aegis.org\/news\/re\/2006\/RE060429.html"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB27|cit27","unstructured":"Muhindo R Bwana M Gupta R Emenyonu N T+Ragmand K Bangsberg D. Treatment change and discontinuation among HIV+ persons treated with fixed-dose generic stavudine, lamivudine and nevirapine in Mbarara, Uganda 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB28|cit28","unstructured":"Sow P Otieno C Bissagnene E et\u00a0al. Implementation of an antiretroviral therapy access program for HIV-infected individuals in resource-limited settings: clinical results from 4 African countries 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team","volume":"341","author":"Staszewski","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB31|cit31","unstructured":"Tashima K Staszewski S Morales-Ramirez J Rachlis A Skiest D Ruiz N Aznar E 3-year durability of response with an efavirenz (EFV)-containing regimen: 144\u2003week follow-up of Study 006 1st International AIDS Society Conference on HIV Pathogenesis and Treatment 2001"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB32|cit32","unstructured":"Moyle GJ Nelson M Ruiz N et\u00a0al Time to treatment success: 24\u2003weeks is not enough in patients starting with high viral load in DP-006 40th Interscience Conference on Antimicrobial Agents & Chemotherapy 2000"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB33|cit33","volume-title":"Durable viral suppression on EFV-based HAART: 168\u2003weeks of follow-up","author":"Tashima","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00126334-200404010-00003","article-title":"Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study)","volume":"35","author":"Pulido","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB35|cit35","volume-title":"Response to therapy in patients with advanced HIV disease","author":"Gray","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection","volume":"349","author":"Robbins","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB37|cit37","volume-title":"Virological and Immunological Outcomes at 3\u2003Years following Initiation of ART with Regimens Containing a NNRTI or PI or both: The INITIO Trial","author":"Cooper","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB38|cit38","volume-title":"Long-term results of a controlled, randomised, prospective trial comparing once- and twice-daily HAART","author":"Maggiolo","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002030-200201040-00008","article-title":"Virological suppression at 6\u2003months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study","volume":"16","author":"Matthews","year":"2002","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB40|cit40","volume-title":"A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV infection-ACTG 5142","author":"Riddler","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB41|cit41","volume-title":"Immunological reconstitution in severely immunosuppressed antiretroviral-naive patients","author":"Miro","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB42|cit42","volume-title":"Antiviral activity of lopinavir\/ritonavir-based regimens in subjects with CD4 cell counts below 25\/mm3","author":"King","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","volume":"19","author":"Van Leth","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB44|cit44","volume-title":"Efavirenz (EFV)-based regimens are potent in treatment-na\u00efve subjects across a wide range of pre-treatment HIV-1 RNA (VL) and CD4 cell counts: 3-year results form ACTG 5095 (A5095)","author":"Ribaudo","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB45|cit45","volume-title":"Head-to-head comparison of two first-line recommended anti-HIV regimens for antiretroviral naive patients: Efavirenz and lopinavir-ritonavir","author":"Manfredi","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.qai.0000243092.40490.26","article-title":"Long-term results of initial therapy with abacavir and lamivudien combined with efavirenz, amprenavir\/ritonavir, or stavudine","volume":"43","author":"Bartlett","year":"2006","journal-title":"J Acquir immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB47|cit47","unstructured":"Montaner JSG Saag M Barylski C et\u00a0al Focus Study: saquinavir qd regimen versus efavirenz qd regimen; 48\u2003week analysis of HIV infected patients 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy 2002"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"190-5","DOI":"10.1093\/jac\/dki172","article-title":"Exploratory analysis for the evaluation of lopinavir\/ritonavir versus efavirenz based HAART regimens in antiretroviral na\u00efve HIV-positive patients: results from the Italian MASTER Cohort","volume":"56","author":"Torti","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jac\/dkh329","article-title":"A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts","volume":"54","author":"Waters","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB51|cit51","doi-asserted-by":"crossref","unstructured":"Bartlett JA Fath MJ DeMasi R et\u00a0al An updated systematic overview of triple combination therapy in antiretroviral-na\u00efve HIV-infected subjects 13th Conference on Retroviruses and Opportunistic Infections 2006","DOI":"10.1097\/01.aids.0000247578.08449.ff"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/375598","article-title":"Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection","volume":"37","author":"Maggiolo","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB53|cit53","unstructured":"Mart\u00ednez E Arnaiz J De Lazzari E Cruceta A Gatell J and The NEFA Study Team 3-year Final Results of a Simplification Trial with Nevirapine, Efavirenz, or Abacavir as Substitutes of Protease Inhibitors in Patients with HIV Infection (The NEFA Study) 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48\u2003weeks efficacy, safety and adherence results","volume":"4","author":"Katlama","year":"2003","journal-title":"HIV Medicine"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB56|cit56","first-page":"257","article-title":"Induction with abacavir\/lamivudine\/zidovudine plus efavirenz for 48\u2003weeks followed by 48-week maintenance with abacavir\/lamivudine\/zidovudine alone in antiretroviral-na\u00efve HIV-1-infected patients","volume":"39","author":"Markowitz","year":"2005","journal-title":"JAIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB57|cit57","unstructured":"Moyle G Nelson M Higgs C et\u00a0al A randomised open label comparative study of combivir + efavirenz (2 class triple therapy) versus trizivir + tenofovir (single class quadruple therapy) in initial therapy for HIV-1 infection 44th Interscience Conference of Antimicrobial Agents and Chemotherapy 2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dki170","article-title":"Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol","volume":"56","author":"Latham","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/339821","article-title":"Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study","volume":"185","author":"Cozzi-Lepri","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1097\/00002030-200112070-00006","article-title":"Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients","volume":"15","author":"Phillips","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1310\/M47B-R51C-X0MC-K3GW","article-title":"Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study","volume":"3","author":"Keiser","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB64|cit64","volume-title":"Durability of efavirenz compared to nevirapine with long term follow-up of an antiretroviral naive cohort","author":"Matthews","year":"2003"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","article-title":"Scaling up of highly active antiretroviral therapy in arural district of Malawi: an effectiveness assessment","volume":"367","author":"Ferradini","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10096-002-0823-0","article-title":"Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy","volume":"21","author":"Macias","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB68|cit68","unstructured":"Rockstroh J Mocroft A Soriano V et\u00a0al INFLUENCE OF HEPATITIS C COINFECTION ON HIV DISEASE PROGRESSION WITHIN THE EUROSIDA COHORT 9TH EUROPEAN AIDS CONFERENCE (EACS) 2003"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1468-1293.2004.00207.x","article-title":"HIV and hepatitis C coinfection within the CAESAR study","volume":"5","author":"Amin","year":"2004","journal-title":"HIV Medicine"},{"issue":"S1","key":"10.1111\/j.1742-1241.2006.01146.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcv.2004.09.001","article-title":"Prevalence of HCV co-infection in HIV-infected in Nigeria and characterisation of HCV genotypes","volume":"31","author":"Agwale","year":"2004","journal-title":"J Clin Virol"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/01.aids.0000180791.85003.3b","article-title":"Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir\/ritonavir","volume":"19","author":"Bonfanti","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB72|cit72","volume-title":"Hepatic Steatosis in HIV\/HCV-co-infected Patients Receiving ART","author":"Martinez","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB74|cit74","unstructured":"Boyle B et\u00a0al. Guide to Management of NNRTI Toxicities and Side Effects http:\/\/www.HIVandHepatitis.com"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1086\/431606","article-title":"Appropriate Use of Nevirapine for Long-Term Therapy","volume":"192","author":"Leith","year":"2005","journal-title":"Journal of Infectious Diseases"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1468-1293.2006.00369.x","article-title":"Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy","volume":"7","author":"Lyons","year":"2006","journal-title":"HIV Medicine"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB79|cit79","unstructured":"Benhamou Y Mats V Walczak D Systemic Overview of HAART-associated Liver Enzyme Elevations in Patients Infected with HIV and Co-infected with HCV 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB80|cit80","unstructured":"Viramune\u00ae Summary of Product Characteristics http:\/\/www.emc.medicines.org"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB82|cit82","first-page":"2353","article-title":"Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up","volume":"18","author":"Calmy","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB83|cit83","unstructured":"Telzir\u00ae Summary of Product Characteristics http:\/\/www.emc.medicines.org"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine","volume":"18","author":"Macias","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB86|cit86","unstructured":"BHIVA Guidelines: HIV and chronic hepatitis: co-infection with HIV and hepatitis C virus infection 2005 http:\/\/www.bhiva.org"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.aids.0000200537.86984.0e","article-title":"Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV: HBV genotype G found to be associated with liver fibrosis","volume":"20","author":"Lacombe","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/00002030-200404090-00016","article-title":"Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir","volume":"18","author":"Haerter","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB89|cit89","unstructured":"Nelson M Personal correspondence"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1468-1293.2005.00273.x","article-title":"Effects of HIV Disease on Lipid, Glucose and Insulin Levels: Results From a Large Antiretroviral-Naive Cohort","volume":"6","author":"El-Sadr","year":"2005","journal-title":"HIV Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB91|cit91","unstructured":"Malan N Krantz E David N et\u00a0al Efficacy and Safety of Atazanavir-based Therapy in Antiretroviral Naive HIV-1 Infected Subjects, Both with and without Ritonavir: 48-week Results from AI424-089 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-na\u00efve patients infected with HIV-1","volume":"1","author":"Van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz versus lipid-lowering therapy for the management of dyslipidaemia","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB219|cit94","unstructured":"Carr A Grund B Neuhaus J et\u00a0al Antiretroviral therapy and asymptomatic ischaemic heart disease in HIV-infected adults: a cross-sectional analysis of patients enrolling in the SMART trial 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB95|cit95","unstructured":"Friss-Moller N Reiss P El-Sadr W et\u00a0al Teh D:A:D Study Group Exposure to PI and NNRTI and risk of myocardial infarction: results of the D:A:D Study 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB96|cit96","unstructured":"Klein D Hurley L Quesenberry C et\u00a0al Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: changes in practice and Framingham risk scores 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.aids.0000222074.45372.00","article-title":"Antiretroviral Medications Associated With Elevated Blood Pressure Among Patients Receiving Highly Active Antiretroviral Therapy","volume":"20","author":"Crane","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB98|cit98","unstructured":"Clifford DB Evans S Yang Y et\u00a0al ACTG 5097s: impact of efavirenz (EFV) on neuropsychological performance, mood, and sleep behaviour in HIV-positive individuals 2nd International AIDS Society Conference on HIV"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB99|cit99","unstructured":"Poupard M Ngom N Thiam D et\u00a0al Quality of life and depression among HIV+ patients receiving efavirenz- or protease inhibitor-based HAART in Dakar, Senegal 13th Conference on Retroviruses and Opportunistic Infections 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB100|cit100","unstructured":"Rode R Vrijens B Niemi K et\u00a0al Differences in treatment compliance between lopinavir\/ritonavir (LPV\/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes 45th Interscience Conference on Antimicrobial Agents & Chemotherapy 2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB101|cit101","unstructured":"Package Insert. Atripla\u00ae (efavirenz\/emtricitabine\/tenofovir) Bristol Myers Squibb & Gilead Sciences"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB102|cit102","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/JVI.68.3.1660-1666.1994","article-title":"Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy","author":"Richman","year":"1994","journal-title":"J Virol"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1468-1293.2004.00208.x","article-title":"Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance","volume":"5","author":"Mackie","year":"2004","journal-title":"HIV Medicine"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB104|cit104","unstructured":"Zala C Salom\u00f3n H Ochoa C et\u00a0al Supervised treatment interruption (STI) following d4T\/ddI\/nevirapine initiated within six months of seroconversion First International Conference on HIV Treatment and Pathogenesis 2001"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB106|cit106","unstructured":"The Antiretroviral Pregnancy Register - 1 January 1989-31 January 2005 http:\/\/www.apregistry.com\/forms\/report105.pdf"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB107|cit107","unstructured":"Sustiva\u00ae (Efavirenz) Summary of Product Characteristics Bristol-Myers Squibb Pharmaceuticals Ltd."},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00126334-200407010-00002","article-title":"For the PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022","volume":"36","author":"Hitti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)14341-3","article-title":"Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial","volume":"362","author":"Jackson","year":"2003","journal-title":"The Lancet"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/367898","article-title":"A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human innumodeficiency virus type-1","volume":"187","author":"Moodley","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(02)08214-4","article-title":"The Petra Study Team: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): A randomised, double blind, placebo-controlled trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jama.288.2.189","article-title":"Two-dose intrapartum\/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomised trial","volume":"288","author":"Dorenbaum","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB113|cit113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB114|cit114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB115|cit115","unstructured":"Jourdain G Ngo-Giang-Huong N Tungyai P et\u00a0al Exposure to intrapartum single-dose nevirapine and subsequent maternal 6\u2003month response to NNRTI-based regimens 11th Conference on Retroviruses and Opportunistic Infections 2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB116|cit116","unstructured":"Zijenah L Kadzirange G Rusakaniko R et\u00a0al Community-based generic antiretroviral therapy following single-doe nevirapine or short-course AZT in Zimbabwe 12th Conference on Retroviruses and Opportunistic Infections 2005"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB117|cit117","unstructured":"Coovadia A Marais B Abrams E et\u00a0al Virologic response to NNRTI treatment among women who took single-dose nevirapine 18 to 36\u2003months earlier 13th Conference on Retroviruses and Opportunistic Infections CROI 2006"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB118|cit118","unstructured":"Mellors J Palmer S Nissley D et\u00a0al Low-frequency NNRTI-resistant Variants Contribute to Failure of Efavirenz-containing Regimens 11th CROI 2004"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/430764","article-title":"Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP","volume":"192","author":"Eshleman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB120|cit120","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/01.aids.0000194800.43799.94","article-title":"Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns","volume":"19","author":"Eshleman","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB121|cit121","unstructured":"McIntyre J Martinson N Boltz V et\u00a0al. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for prevention of mother-to-child transmission of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus XV Intl AIDS Conference"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB122|cit122","doi-asserted-by":"crossref","unstructured":"Pozniak AL Miller RH Lipman MCI et\u00a0al on behalf of the BHIVA guidelines writing committee BHIVA treatment guidelines for TB\/HIV infection February 2005 http:\/\/www.bhiva.org","DOI":"10.1111\/j.1468-1293.2005.00293.x"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB123|cit123","first-page":"681","volume-title":"Clin Pharmacokinet","volume":"41","author":"Lopez-Cortes","year":"2002"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB124|cit124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600\u2003mg\/day versus efavirenz 800\u2003mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48\u2003weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01146.x-BIB125|cit125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000174445.40379.e0","article-title":"The potential for interactions between antimalarial and antiretroviral drugs","volume":"19","author":"Khoo","year":"2005","journal-title":"AIDS"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01146.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:08Z","timestamp":1643349908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01146.x"}},"subtitle":["NNRTIs: a review"],"short-title":[],"issued":{"date-parts":[[2007,1,8]]},"references-count":125,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01146.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1,8]]}}}